Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?

about

Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival

P2860

Q33809495-048FC5B3-53B7-4774-9178-99CD99A229C5

P2860

Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?

Item

http://www.wikidata.org/entity/Q38161359

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Neoadjuvant therapy in patient ...... pointing therapeutic approach?

@en

type

Item

label

Neoadjuvant therapy in patient ...... pointing therapeutic approach?

@en

prefLabel

Neoadjuvant therapy in patient ...... pointing therapeutic approach?

@en

P1476

Neoadjuvant therapy in patient ...... pointing therapeutic approach?

@en

P2093

Carolin Zimmermann

http://www.w3.org/2001/XMLSchema#string

Daniel Zips

http://www.w3.org/2001/XMLSchema#string

Robert Grutzmann

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplina

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.

Combined modality therapy for stage II and stage III pancreatic carcinoma.

Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.

Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas.

P304

2286-2301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS3022286

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Detlev Saeger

Christian Pilarsky

Gunnar Folprecht

P577

2011-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258429659

http://www.w3.org/2001/XMLSchema#string

P698

24212810

http://www.w3.org/2001/XMLSchema#string

P932

3757418

http://www.w3.org/2001/XMLSchema#string

Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?

about

P2860

P2860

Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932